Literature DB >> 19286756

Meta-analysis of association of ACE2 G8790A polymorphism with Chinese Han essential hypertension.

Jian-Bo Zhou1, Jin-Kui Yang.   

Abstract

INTRODUCTION: We performed a meta-analysis to assess the association of ACE2 G8790A polymorphism with essential hypertension.
MATERIALS AND METHODS: The references were retrieved through MEDLINE, Wanfang and VIP Information.The analyses were performed by the software STATA 9.0.
RESULTS: No significant publication bias was observed.The combined data showed no association of the frequencies of the A allele with essential hypertension odds ratio (OR)=1.09 95% confidence interval (CI)=0.98-1.20;p=0.11 in female patients. No associations were shown between the frequencies of the A allele with the genetic susceptibility to essential hypertension in male patients (OR=1.11 95% CI=0.95-1.29; p=0.19).
CONCLUSION: The meta-analysis suggests that ACE2 G8790A polymorphism may not be a genetic risk factor for essential hypertension in a Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286756     DOI: 10.1177/1470320309103047

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  11 in total

1.  ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects.

Authors:  Na Lu; Yang Yang; Yibo Wang; Yan Liu; Gang Fu; Dongmei Chen; Hui Dai; Xiaohan Fan; Rutai Hui; Yang Zheng
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

2.  The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke.

Authors:  Yan-Hui Wu; Jia-Ying Li; Chi Wang; Li-Mei Zhang; Hong Qiao
Journal:  J Clin Lab Anal       Date:  2016-08-08       Impact factor: 2.352

3.  COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?

Authors:  Donato Gemmati; Barbara Bramanti; Maria Luisa Serino; Paola Secchiero; Giorgio Zauli; Veronica Tisato
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

4.  Lack of Association of ACE2 G8790A Gene Mutation with Essential Hypertension in the Chinese Population: A Meta-Analysis Involving 5260 Subjects.

Authors:  Yan-Yan Li
Journal:  Front Physiol       Date:  2012-09-12       Impact factor: 4.566

Review 5.  Angiotensin-converting enzyme 2 as a therapeutic target for heart failure.

Authors:  Mohammed A R Chamsi-Pasha; Zhili Shao; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 6.  From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension.

Authors:  Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell
Journal:  Front Physiol       Date:  2014-06-24       Impact factor: 4.566

Review 7.  ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; Sayaka Nagata; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2014-03       Impact factor: 5.369

8.  Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19.

Authors:  Riadh Badraoui; Mousa M Alrashedi; Michèle Véronique El-May; Fevzi Bardakci
Journal:  J Biomol Struct Dyn       Date:  2020-08-05

9.  Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study.

Authors:  Qi Zhang; Mingyu Cong; Ningning Wang; Xueyan Li; Hao Zhang; Keyong Zhang; Ming Jin; Nan Wu; Changchun Qiu; Jingping Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

10.  Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19.

Authors:  Donato Gemmati; Veronica Tisato
Journal:  Genes (Basel)       Date:  2020-09-03       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.